Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Family Medicine · KNOXVILLE, TN · NPI 1346335957
Verified facts
CMS Open Payments records show Jonathan Daniel Dee, MD received $51.55 in general payments during 2025 across 1 reported records.
HEARTFLOW, INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $51.55 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $51.55 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $51.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 200 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 163 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 41 |
| Lisinopril | Lisinopril | 106 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 99 | 30 |
| Losartan Potassium | Losartan Potassium | 97 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 91 | 31 |
| Alendronate Sodium | Alendronate Sodium | 82 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 28 |
| Omeprazole | Omeprazole | 77 | 24 |
| Alprazolam | Alprazolam | 74 | 15 |
| Simvastatin | Simvastatin | 66 | 20 |
| Gabapentin | Gabapentin | 64 | 18 |
| Finasteride | Finasteride | 62 | 19 |
| Trazodone Hcl | Trazodone Hcl | 62 | 21 |
| Meloxicam | Meloxicam | 61 | 19 |
| Montelukast Sodium | Montelukast Sodium | 60 | 25 |
| Carvedilol | Carvedilol | 56 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 11 |
| Valsartan | Valsartan | 52 | 23 |
| Metformin Hcl Er | Metformin Hcl | 51 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 15 |
| Eliquis | Apixaban | 50 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 17 |
| Benazepril Hcl | Benazepril Hcl | 45 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 43 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 11 |
| Metformin Hcl | Metformin Hcl | 41 | 13 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 11 |
| Famotidine | Famotidine | 37 | 11 |
| Sertraline Hcl | Sertraline Hcl | 34 | 11 |
| Lorazepam | Lorazepam | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Prednisone | Prednisone | 32 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | 12 |
| Temazepam | Temazepam | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 18 |
| Furosemide | Furosemide | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Celecoxib | Celecoxib | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Xanax | Alprazolam | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $51.55 · 1 records | HEARTFLOW, INC. | FFRct | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error